NCT03162536View on ClinicalTrials.gov

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

September 18, 2026

Study Completion Date

September 18, 2026

Conditions
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaWaldenstrom MacroglobulinemiaMantle Cell LymphomaDiffuse Large B Cell LymphomaRichter's TransformationFollicular LymphomaMarginal Zone Lymphoma
Interventions
DRUG

Nemtabrutinib

Nemtabrutinib will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg. For Expansion Food Effect Cohort I, nemtabrutinib will be orally administered once per day under fasted and non-fasted condition.

Trial Locations (10)

27710

Duke Cancer Center ( Site 0067), Durham

37203

Tennessee Oncology, PLLC ( Site 0020), Nashville

43210

The Ohio State University Wexner Medical Center ( Site 0056), Columbus

48109

University of Michigan ( Site 0018), Ann Arbor

58905

Mayo Clinic - Rochester ( Site 0138), Rochester

80218

Colorado Blood Cancer Institute ( Site 0225), Denver

84112

University of Utah, Huntsman Cancer Institute ( Site 0122), Salt Lake City

85259

Mayo Clinic Hospital ( Site 0140), Scottsdale

90095

UCLA Hematology & Oncology ( Site 0017), Los Angeles

75390-8562

UT Southwestern Medical Center ( Site 0116), Dallas

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT03162536 - A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | Biotech Hunter | Biotech Hunter